Skip to main content
From the Literature
Concise Reviews of Studies Relevant to Hematology Oncology Pharmacy
Read More
Leukemia, FDA Updates
Quizartinib Significantly Improves Survival Over Chemotherapy in Patients with Relapsed/Refractory AML and FLT3-ITD Mutation
Read More
FDA Updates
Welcome to the Third Annual Oncology Guide to New FDA Approvals
Read More
FDA Updates
FDA Approvals in 2017 Represent a 21-Year High
Gary M. Owens, MD
Read More
FDA Updates
FDA Approvals of Brand-Name Prescription Cancer Drugs in 2017
Read More
FDA Updates, Lung Cancer
Alunbrig (Brigatinib) Approved for Metastatic NSCLC with ALK Mutation
Lisa A. Raedler, PhD, RPh, Medical Writer
Read More
FDA Updates, Lymphoma
Calquence (Acalabrutinib) Approved for Relapsed or Refractory Mantle-Cell Lymphoma in Adults
Lisa A. Raedler, PhD, RPh, Medical Writer
Read More
FDA Updates, Lymphoma
Imbruvica (Ibrutinib) First Drug Approved Specifically for Marginal-Zone Lymphoma and for Chronic Graft-versus-Host Disease
Lisa A. Raedler, PhD, RPh, Medical Writer
Read More
FDA Updates, Bladder Cancer
Imfinzi (Durvalumab) a New PD-L1 Inhibitor Approved for the Treatment of Advanced or Metastatic Urothelial Cancer
Lisa A. Raedler, PhD, RPh, Medical Writer
Read More
FDA Updates, Breast Cancer
Kisqali (Ribociclib): Second CDK4/CDK6 Inhibitor Approved for Postmenopausal Women with HR-Positive, HER2-Negative Advanced Breast Cancer
Lisa A. Raedler, PhD, RPh, Medical Writer
Read More
Page 161 of 200
Results 1601 - 1610 of 1993